ArticleCancer management and research2026
Dual Role of AITD in TgAb-Positive PTC: Delayed Antibody Clearance with Enhanced RAIT Response.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Elevated thyroglobulin antibody (TgAb) levels in postoperative management of papillary thyroid carcinoma (PTC) are often attributed to tumor recurrence, while the potential impact of autoimmune thyroid disease (AITD) is overlooked. This study aims to clarify the comprehensive effects of AITD on baseline TgAb levels, antibody normalization kinetics, pre-RAIT persistent structural disease risk, and radioactive iodine therapy (RAIT) efficacy in PTC patients. Methods: A retrospective cohort of 287 TgAb-positive (≥115 IU/mL) PTC patients who underwent total thyroidectomy and received RAIT with ≥6 months follow-up was enrolled. Based on postoperative pathology and thyroid peroxidase antibody (TPOAb) status, patients were divided into Group A0 (non-AITD, n=70) and Group A1 (AITD-concurrent, n=217). Clinicopathological characteristics, RAIT response, and TgAb normalization were compared. Results: Among TgAb-positive PTC patients, 75.6% had concurrent AITD. Group A1 exhibited higher pre-RAIT TgAb levels (740.0[450.0-1050.0] vs 520.5[300.0-800.0]IU/mL, Z = -2.155, Conclusion: Concurrent AITD is associated with elevated TgAb, delayed antibody clearance, and increased pre-RAIT persistent structural disease risk, yet does not compromise RAIT efficacy. This highlights the dual role of AITD in PTC prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.